Core Viewpoint - 招银国际 has raised the target price for复宏汉霖 from HKD 20.33 to HKD 61.98, indicating strong potential for growth in the innovative drug development sector [1] Company Summary - 复宏汉霖 is transitioning from a profitable biosimilar company to a leading player in the biopharmaceutical field, with several innovative drugs such as HLX43, HLX22, and Serplulimab showing promising clinical data [1] - The company is actively expanding its global biosimilar business through partnerships with pharmaceutical companies, with strong commercialization performance from 汉曲优 (Trastuzumab) and Serplulimab [1] - The FDA is currently reviewing the market approval applications for HLX14 and HLX11, which are expected to contribute to overseas revenue sources [1]
招银国际一举升复宏汉霖目标价至61.98港元 料创新药研发有庞大潜力